Cannabis Science Has US Federal Government Clearance that Changes the Industry, Access to Federal Government Contracts, Supported US Federal Governments Since 2009, Looks for New Federal Policy to Properly Regulate Industry for Patients


IRVINE, CA, Jan. 05, 2018 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce its support for the U.S. Federal Government, and the Company intends to step in with its experts to assist the Federal Government. The Company is looking to establish new Federal marijuana policy and calls on Department of Justice (DOJ) to help establish a properly-regulated Federal Policy for all patients’ safe access to pharmaceutical and pharmacy dispensed cannabinoids for various critical ailments.

Cannabis Science has launched several initiatives to study the use of cannabinoid-based medicines. For one such initiative, initial results on using nanoparticle drones to target and successfully kill stage four lung cancer cells with radiosensitizers and cannabinoids have been published in the cancer research journal “Frontiers in Oncology”.

The article can be viewed at https://www.frontiersin.org/articles/10.3389/fonc.2017.00208/full

This publication of our work has clearly documented our success in a one of the leading Oncology publications as evidence of our cannabinoid research expertise. “Nanoparticle drones to target lung cancer with radiosensitizers and cannabinoids,” addresses drug delivery, and highlights an innovative strategy to deliver cannabinoids directly to cancer cells with minimal toxicities or side effects that have so far hampered clinical translation efforts.

Equally important, Cannabis Science has the grit in the industry: it has been registered and received its initial Federal Commercial and Government Entity (CAGE) Code clearance back in 2009. Cannabis Science is one of the only companies in its industry with the ability to work directly with the US Federal Government. Cannabis Science clearly intends to use its relationships and vast expertise within its team from a number of Government Agencies, University Medical Research, Government Medical Research, Pharmaceutical Drug Development, Pharmacy Dispensing, and a number of other key points on this matter. Cannabis Science will promptly address the divergences with the Federal Government and the American people who are actually looking to treat their ailments using pharmaceutical and pharmacy dispensed cannabinoids across the Country.

“As a research-based company, CBIS’ focus is on pharmaceutical drug development and on creating medicines that can help patients in need,” stated Dr. Allen Herman, CBIS’ Chief Medical Officer. “We believe there are a number of indications that can be effectively treated with cannabinoid-based medicines and we expect our research, development, and clinical trial initiatives to demonstrate this.”

The U.S. Federal Government clearance clearly places Cannabis Science as one of THE Leading Publicly Traded Company in this industry looking to establish a Federal regulatory governing body to convene over the laws, regulations and compliance of the cannabis industry. Cannabis Science, Inc. has also conducted its business in this manner since the 2009 approval from the U.S. Federal Government as if these policies and procedures had been established at a Federal level. Cannabis Science, Inc. wants to work hand in hand with the establishment of federal laws and regulations, work within the federal laws and regulations that already exist and with the federal agencies charged with enforcing them.

Cannabis Science is registered in SAM with three North American Industry Classification System (NAICS) Codes:

  • 541711 – Research and Development in Biotechnology 
  • 621511 – Medical Laboratories
  • 624230 – Emergency and Other Relief Services

“Cannabis Science is currently exploring a number of Federal government contracts and grant opportunities, individually and with its collaborators, with institutions such as the National Institutes of Health (NIH), institutes within NIH, such as the National Institute on Drug Abuse (NIDA), and others. There is a certain level of clearance Cannabis Science has received from the Defense Logistics Agency’s CAGE Program Office at the U.S. Department of Defense for the Federal Commercial and Government Entity (CAGE) Code program that allows CBIS instant access to U.S. Federal Government contract procurement and that puts the Company directly in line to benefit from the cannabinoid-based medicines industry,” stated Mr. Dabney. “As for the U.S. Federal Government, we believe we have a significant role to play, as a private sector stakeholder, as well as a company that can support federally-funded contracts and grant opportunities as an experienced contractor. Our Team is honored to be a part of the process involved with the establishment of these Laws, Policies, Regulations and Compliance and possibly become a part of the business model for the private sector to adhere to.”

About Cannabis Science, Inc.

Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Forward-Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these  forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company's reports filed with the Securities and Exchange Commission.



        

Contact Data